The EPS miss is overshadowed by strong Ryoncil revenue trajectory, pipeline catalysts (CLBP Phase 3 enrollment complete, adult SR-aGvHD trial starting, DMD IND cleared), and cash conservation. The stock has already repriced higher on prior catalysts, watch for CLBP Phase 3 top-line data readout and adult SR-aGvHD trial enrollment updates as next key events. The CAR-MSC platform acquisition adds optionality in autoimmune indications.
MESO drugs
MESO drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 30 $15.67entry
- T+1 · 7mo ago +0.45%α +0.23% · $15.74
- T+5 · 6mo ago −5.55%α −7.28% · $14.80
- T+20 · 6mo ago −1.72%α −6.95% · $15.40
- T+60 · 4mo ago −7.08%α −10.19% · $14.56
Price Chart
How similar events traded
Executive Summary
Mesoblast reported Q3 FY2026 results with Ryoncil net revenue of $30.3M, bringing cumulative launch revenue to ~$100M. EPS of -$0.07 missed consensus of -$0.03, but the company achieved its pivotal Phase 3 trial recruitment target for chronic low back pain and reduced net operating cash spend to $4.1M.
Key Financial Metrics
Key Facts
- Ryoncil net revenue $30.3M for Q3 FY2026; cumulative launch revenue approaching $100M
- EPS -$0.07 vs consensus -$0.03 (133% miss)
- Net operating cash spend reduced to $4.1M from prior levels
- Cash balance $122M at March 31, 2026
- Pivotal Phase 3 trial for rexlemestrocel-L in chronic low back pain achieved patient recruitment target
- FDA cleared label extension trial for Ryoncil in adult SR-aGvHD; IND clearance for Duchenne muscular dystrophy registrational trial
- Acquired exclusive worldwide license to CAR technology platform for precision-enhanced MSC products
- Inaugural R&D day held April 8 highlighting label expansion and blockbuster opportunities
Financial Impact
Ryoncil revenue run-rate approaching $120M annualized; net cash spend reduced to $4.1M/quarter; $122M cash position provides ~7 years of runway at current burn
Risk Factors
- EPS miss of 133% vs consensus may pressure near-term sentiment
- Ryoncil revenue growth trajectory depends on continued commercial execution and label expansion approvals
- CLBP Phase 3 trial success is not guaranteed; failure would remove a major pipeline value driver
- Dilution risk from potential future capital raises despite current $122M cash position
- Biotech sector volatility and OTC listing may amplify price swings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3284394 |
Track record
25 reports on MESO
6 of 14 bullish or bearish reports moved the stock their way by T+1. Best: +24.95% at T+20 after the Jul 30, 2026 report. 9 of 14 went positive at some point.
Filters
- Nov 16, 2026today 6-K Neutral 2/10 Entry $13.25 Now $12.45 −6.04% settles Nov 17
- Nov 10, 20266d ago 6-K Neutral 3/10 Entry $13.65 to $13.10 Now $12.45 −8.79% ▼ −4.03% −3.68% vs SPY
- Nov 2, 202614d ago 6-K Neutral 2/10 Entry $14.77 to $14.29 Now $12.45 −15.71% ▼ −3.25% −4.90% vs SPY
- Oct 29, 202618d ago 6-K Bullish 6/10 No price data
- Oct 28, 202619d ago Press Release Bullish 6/10 Entry $15.67 to $15.16 Now $12.45 −20.55% ▼ −3.25% −1.48% vs SPY
- Oct 15, 20264w ago 6-K Bullish 6/10 Entry $13.28 to $11.95 Now $12.45 −6.25% ▼ −10.02% −10.44% vs SPY
- Oct 15, 20264w ago 6-K Neutral 2/10 Entry $13.95 to $13.28 Now $12.45 −10.75% ▼ −4.80% −3.70% vs SPY
- Oct 13, 20264w ago 6-K Mixed 6/10 Entry $13.90 to $13.79 Now $12.45 −10.40% ▼ −0.76% +0.33% vs SPY
- Sep 23, 20267w ago 6-K Neutral 3/10 Entry $15.48 to $15.12 Now $12.45 −19.57% ▼ −2.33% −2.87% vs SPY
- Aug 27, 202611w ago 20-F Bullish 6/10 Entry $18.18 to $17.44 Now $12.45 −31.52% ▼ −4.07% −3.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers